Annals of internal medicine: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response

Annals of Internal Medicine

Volumn 126, Issue 12, 1997, Pages 929-938

  Hughes, Michael D ^a   Johnson, Victoria A ^b   Hirsch, Martin S ^c   Bremer, James W ^d   Elbeik, Tarek ^e   Erice, Alejo ^f   Kuritzkes, Daniel R ^g   Scott, Walter A ^h   Spector, Stephen A ⁱ   Basgoz, Nesli ^c   Fischl, Margaret A ^h   D'Aquila, Richard T ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

^f University of Minnesota   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS TITRATION; ADULT; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG COMBINATION; GENETICS; METHODOLOGY; MONITORING; PHENOTYPE; PROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; MONITORING, PHYSIOLOGIC; NEVIRAPINE; PHENOTYPE; PROSPECTIVE STUDIES; PYRIDINES; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0031570404     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-12-199706150-00001     Document Type: Article

References (38)

1. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of polymerase chain reaction. J Infect Dis. 1991;163:862-6.
2. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
3. Lin HJ, Myers LE, Yen-Lieberman B, Hollinger FB, Henrard D, Hooper CJ, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis. 1994;170:553-62.
4. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-9.
5. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995;332:201-8.
6. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995;332:209-16.
7. + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-31.
8. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-70.
9. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996; 174:704-12.
10. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996;174:696-703.
11. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996;335:1091-8.
12. Gupta P, Kingsley L, Armstrong J, Ding M, Cottrill M, Rinaldo C. Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology. 1993;196:586-95.
13. Fiscus SA, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA 3d, LoFaro ML, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis. 1995;171:305-11.
14. Hooper CJ, Coombs RW, Boutin PD, Collier AC, Corey L. Increases in CD4 cell count are associated with decreases in HIV-1 viral load in patients changing antiretroviral regimens. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:1152.
15. + cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-8.
16. Richman DD, Bozette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994; 169:968-74.
17. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi J, Liou SH, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med. 1996; 124:1019-30.
18. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987;36(Suppl 1):1S-15S.
19. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry. 1993;14:702-15.
20. Gelman R, Cheng SC, Kidd P, Waxdal M, Kagan J. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. Clin Immunol Immunopathol. 1993,66:150-62.
21. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol. 1994;32:732-9.
22. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol. 1994;32:2291-4.
23. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
24. Draper NR, Smith H. Applied Regression Analysis. 2d ed. New York: Wiley; 1981:70-108.
25. Clayton D, Hills M. Statistical Models in Epidemiology. New York: Oxford Univ Pr; 1993:229-33.
26. Armitage P, Berry G. Statistical Methods in Medical Research. 3d ed. Boston: Blackwell Scientific; 1994:219-21.
27. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society Series B. 1972;34:187-220.
28. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54.
29. Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, et al. HIV-1 RNA levels and the development of clinical disease. AIDS. 1996;10:859-65.
30. Wathen LK, Nickens DJ, Chuang-Stein CJ, Crampton DJ, Mickelson PM, Carberry PA et al. HIV-1 RNA viral burden at baseline or its reduction following antiretroviral therapy is highly correlated with reduced HIV-1 disease progression. In: Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC: Infectious Diseases Society of America; 1996:LB8c.
31. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-9.
32. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-6.
33. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-9.
34. + cell counts, and HIV-1 production by cells [Letter]. Science. 1996; 271:670-1.
35. Ho DD. Viral counts count in HIV infection. Science. 1996;272:1124-5.
36. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-22.
37. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-6.
38. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2:625-9.